Sionna Therapeutics (NASDAQ:SION) Cut to “Neutral” at BTIG Research

BTIG Research cut shares of Sionna Therapeutics (NASDAQ:SION) from a buy rating to a neutral rating in a research report sent to investors on Monday, MarketBeat.com reports.

A number of other equities research analysts have also recently commented on the company. Wall Street Zen cut Sionna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Guggenheim downgraded shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday. Citigroup lowered shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday. Freedom Capital cut shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Wednesday, August 5th. One analyst has rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $42.22.

Sionna Therapeutics Trading Up 22.5%

Shares of SION opened at $6.25 on Monday. The stock has a 50 day moving average of $40.38 and a 200 day moving average of $39.67. The company has a market capitalization of $282.56 million, a price-to-earnings ratio of -2.87 and a beta of 1.33. Sionna Therapeutics has a 12 month low of $4.01 and a 12 month high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.02). As a group, equities research analysts predict that Sionna Therapeutics will post -2.65 earnings per share for the current year.

Insider Buying and Selling at Sionna Therapeutics

In other news, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. This represents a 3.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the transaction, the director directly owned 2,469,959 shares in the company, valued at $110,802,360.74. This represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 403,726 shares of company stock worth $18,259,354. Corporate insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new position in shares of Sionna Therapeutics in the second quarter worth about $80,000. BlackRock Inc. bought a new position in Sionna Therapeutics in the 2nd quarter worth approximately $64,875,000. Deutsche Bank AG purchased a new position in Sionna Therapeutics in the 2nd quarter valued at approximately $2,347,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Sionna Therapeutics during the 2nd quarter valued at $44,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Sionna Therapeutics during the second quarter worth $1,829,000.

Key Stories Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: The stock’s rebound may reflect bargain hunting and short-term volatility following the steep selloff, although no new positive clinical data were reported.
• Neutral Sentiment: Analyst opinion has broadly converged around a more cautious stance. Royal Bank of Canada upgraded SION to “Sector Perform,” while Stifel Nicolaus assigned a “Hold” rating. Royal Bank of Canada upgrade
• Negative Sentiment: Sionna reported that its Phase 2a PreciSION CF trial of lead candidate SION-719 failed to achieve its key endpoint for sweat-chloride reduction. The drug will not advance as an add-on therapy, severely damaging the company’s near-term cystic-fibrosis development prospects. Sionna halts lead cystic fibrosis drug
• Negative Sentiment: The clinical failure erased roughly 90% of SION’s market value and removed a potential competitive threat to Vertex Pharmaceuticals, whose shares benefited from the news. Vertex rises as Sionna trial fails
• Negative Sentiment: Several firms reduced their ratings, including Lifesci Capital and JonesTrading to “Hold,” Wedbush to “Neutral,” Raymond James to “Market Perform,” and BTIG and Guggenheim to lower ratings. These actions signal reduced confidence after the trial result. Wedbush downgrade
• Negative Sentiment: Levi & Korsinsky announced a pending investor investigation into potential securities-law violations related to disclosures that allegedly indicated SION-719 was on track before the failed trial outcome. The investigation adds legal and reputational risk. Sionna investor investigation notice

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.